Inthera, a pharmaceutical company established in 1991 in Budapest, Hungary, has announced it has successfully secured $11.1 million in a recent funding round. This investment marks a significant milestone for the company, which specializes in critical services within the global pharmaceutical sector.
The company's core operations encompass several key areas. Inthera is a primary provider for sourcing pharmaceutical products required for clinical trials, a crucial step in drug development. It also offers comprehensive international regulatory affairs services, guiding clients through complex compliance landscapes. Furthermore, Inthera assists manufacturers located outside the European Union in obtaining their essential EU GMP (Good Manufacturing Practice) licenses, facilitating their access to the European market. The company is also actively involved in the distribution and wholesale of various pharmaceutical products both within and outside the European Union.
The $11.1 million capital infusion reflects strong investor confidence in Inthera's established business model and its vital role in supporting pharmaceutical innovation and supply chains. This funding round is expected to provide the necessary resources for the company to accelerate its strategic objectives. Inthera plans to utilize these funds to expand its operational capabilities, enhance its specialized service offerings, and further strengthen its market position.
This investment is anticipated to fuel Inthera's growth initiatives, allowing it to scale its existing services and explore new opportunities for expansion. The company aims to continue its mission of facilitating pharmaceutical development and ensuring efficient product distribution across international markets, reinforcing its commitment to the global healthcare industry.
